Arvinas is committed to expanding its transformative degradation platform and moving important new therapies into clinical development, and we would welcome discussions on meaningful strategic collaborations.
Our interest in collaborating is to expand the universe of druggable targets with our transformative protein degradation technology.
Opportunities for platform and product deals, include the following:
- Targets of interest to Arvinas
- Targets of interest to partner
- Targets with ligands with suboptimal affinity
- Targets with ligands without function
- Targets with nontraditional binding ligand
You can contact us at BD@arvinas.com.
Arvinas has significant partnerships with Genentech and Pfizer, two of the leading research and development organizations in the industry. We believe their interest in protein degradation as a therapeutic approach to address difficult disease targets offers an exciting opportunity to explore the full potential of PROTACTM protein degraders to harness the body’s ability to degrade disease-causing proteins.
In November 2017, Arvinas and Genentech, a member of the Roche Group, expanded their multi-year strategic license agreement to encompass additional disease targets. The collaboration was formed in October 2015 to develop new therapeutics using Arvinas’ PROTAC® technology platform.
As part of the expansion, Arvinas is now eligible to receive more than $650 million in development and commercialization milestones as well as tiered royalties on sales of products. Genentech has the option to further expand the collaboration to include other disease targets for consideration.
In January 2018, Arvinas announced a research and collaboration license agreement with Pfizer Inc. for the discovery and development of drug candidates using Arvinas’ PROTAC® technology platform, which is designed to degrade harmful target proteins. The multi-year collaboration covers multiple disease targets across several therapeutic areas.
Arvinas may receive up to $830 million in upfront and potential development and commercialization milestone payments in addition to tiered royalties. Arvinas will drive discovery efforts, while Pfizer will be accountable for clinical development and commercialization of any products that may result from the collaboration.
In June of 2019, Arvinas and Bayer announced an agreement to leverage Arvinas’ novel PROTAC® protein degrader technology to develop new human therapeutics for patients with cardiovascular, oncological, and gynecological diseases. Simultaneously, Bayer and Arvinas announced the formation of a separate joint venture (JV), which will leverage Arvinas’ PROTAC protein degrader technology for agricultural applications. The arrangements include over $110 million in upfront cash and committed funding for the human disease collaboration, the agricultural joint venture, and a direct equity investment by Bayer in Arvinas.
In the pharmaceutical collaboration, Bayer and Arvinas will seek to develop a novel product candidates for diseases with serious unmet need. Arvinas will receive an upfront payment and committed R&D funding. When combined with the direct equity investment in Arvinas, these investments exceed $60 million. As programs progress through research, development, and commercialization, Arvinas is also eligible to receive development milestones of over $685 million and commercial royalties ranging from the mid-single digits to the low double-digits. The JV will be supported by intellectual property and over $55 million in committed funding from Bayer, and by technology and intellectual property from Arvinas. Bayer and Arvinas will equally share governance and equity ownership of the JV.